MEMORIAL SLOAN KETTERING CANCER CENTER and Cornell University are opening a new $10 million Center of Cancer Nanotechnology Excellence. The MSKCC-Cornell Center for Translation of Cancer Nanomedicines is funded with an $8.2 million grant from the NCI Alliance for Nanotechnology in Cancer and more than $1.9 million from MSKCC. The center—which will have one facility...
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
